Shanghai Yizhong (688091.SH) announced its half-year report on August 7th, with revenues of 0.12 billion yuan, down 39.17% year-on-year, net income of 34.5089 million yuan, down 66.85% year-on-year, and non-GAAP net income of 33.16 million yuan, down 62.85% year-on-year, and basic earnings per share of 0.17 yuan.
The company's core product, 'paclitaxel injection polymer micelles (ZSHR)', is the first batch of projects of the national 'major new drug creation' science and technology major project 'Thirteenth Five-Year Plan'. This product was approved for market by the National Medical Products Administration as a category 2.2 (innovative formulation that has not been marketed domestically or internationally) innovative drug in October 2021, and is used in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are negative for epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK), and are incurable by surgery, in combination with platinum. The successful launch of this product fills the gap in the field of micelle preparations at home and abroad. In addition to the treatment of NSCLC, paclitaxel micelles are also widely used in the treatment of other types of cancers such as esophageal cancer, gastric cancer, nasopharyngeal cancer, pancreatic cancer, breast cancer, gynecological tumors, and so on, in actual clinical practice.
